QLT Inc. (USA)  

(Public, NASDAQ:QLTI)   Watch this stock  
Find more results for QLTI
1.37
-0.01 (-0.80%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.36 - 1.38
52 week 1.22 - 3.86
Open 1.38
Vol / Avg. 36,047.00/223,916.00
Mkt cap 71.71M
P/E     -
Div/yield     -
EPS -0.74
Shares 52.83M
Beta -0.21
Inst. own 49%
Jul 29, 2016
Q2 2016 QLT Inc Earnings Release (Estimated)
Jun 15, 2016
Aegerion Pharmaceuticals Inc & QLT Inc Agree to Strategic Merger Call - Webcast
May 5, 2016
Q1 2016 QLT Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -65.39% -15.06%
Return on average equity -67.35% -15.45%
Employees 23 -
CDP Score - -

Address

887 Great Northern Way Suite 250
VANCOUVER, BC V5T 4T5
Canada
+1-604-7077000 (Phone)
+1-604-7077001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

QLT Inc. is a biotechnology company. The Company is focused on the development and commercialization of ocular products. The Company's operations consist of clinical development programs focused on its synthetic retinoid, QLT091001, for the treatment of certain age-related and inherited retinal diseases (IRD) caused by retinal pigment epithelium protein 65 (RPE65) and lecithin: retinol acyltransferase (LRAT) gene mutations. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal. The Company is developing QLT091001 for the treatment of IRD caused by RPE65 and LRAT gene mutations, which indication includes Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP). It has completed a Phase Ib clinical proof of concept study and a follow-up retreatment study in LCA and RP patients with autosomal recessive mutations in RPE65 or LRAT, and a Phase 1b study in RP patients with autosomal dominant mutations in RPE65.

Officers and directors

Jason M. Aryeh Independent Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
Geoffrey F. Cox Ph.D. Interim Chief Executive Officer, Director
Age: 71
Bio & Compensation  - Reuters
Glen Ibbott Chief Financial Officer, Senior Vice President - Finance, Principal Accounting Officer
Age: 52
Bio & Compensation  - Reuters
John W. Kozarich Ph.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Jeffrey A. Meckler Independent Director
Age: 48
Bio & Compensation  - Reuters
Stephen L. Sabba M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
John C. Thomas Jr. Independent Director
Age: 61
Bio & Compensation  - Reuters